GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (FRA:7V3) » Definitions » Valuation Rank

Cantargia AB (FRA:7V3) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is Cantargia AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cantargia AB Valuation Rank Related Terms

Thank you for viewing the detailed overview of Cantargia AB's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Cantargia AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (FRA:7V3) » Definitions » Valuation Rank
Comparable Companies
OSTO:LIPUM OSTO:IMMU OSTO:ONCO OSTO:INIT OSTO:ACE XSAT:CURAS OSTO:ALZ OSTO:KDEV OSTO:ISOFOL XSAT:CESSA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
CANTA:Sweden
Address
Scheelevagen 27, Lund, SWE, SE-223 63
Website
https://www.cantargia.com
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.